

Table 2A. MAD 1-3 Safety Procedures

MAD 1-3													
Phase	Prerandomization			Randomization									
Period	Screening	Baseline		Treatment									
Visit	1	2	3	4	5	6	7	8	9	10	11	12	
Day	-60 to -5	-2	-1	1	2	21±2	28	49±2	56	83	84	85	175±5
Procedures/Assessments													
MRI	X					X		X		X			X
Vital signs	X	X		X	X	X	X	X	X	X	X	X	X
Physical Exam	X	X		X		X	X	X	X	X			X
ECG	X	X		X	X		X		X		X		X ^w
Clinical labs (hematology, clinical chemistry, urinalysis)	X		X	X	X	X	X	X	X		X	X	X
C-SSRS	X	X			X	X	X	X	X		X	X	X
Adverse events	X	X	X	X	X	X	X	X	X	X	X	X	X

Table 3A. MAD4 Safety Procedures

MAD4																					
Phase	Prerandomization			Randomization																	
Period	Screening	Baseline		Treatment																	
Visit	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19 (Final / Early Withdrawal)	Unscheduled	
Day	-60 to -5	-2	-1	1/2	7	14	21	28	35	42	49	56	63	70	77	84	85	98	175		
Procedures / Assessments																					
Randomization			X																		
MRI	X						X				X				X				X	X	
Vital signs	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Physical exam	X	X		X	X	X	X	X	X	X	X	X	X	X	X	X		X	X		
ECG	X	X		X		X		X		X		X		X		X	X	X	X	X	
Clinical labs (hematology, clinical chemistry, urinalysis)	X		X	X		X		X		X		X		X		X	X	X	X	X	
C-SSRS	X	X		X		X		X		X		X		X		X	X	X	X	X	
Adverse events	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X